Managed Access Program for Momelotinib in Myelofibrosis

Summary

Compassionate use access to Momelotinib/GSK3070785 for eligible participant with diagnosis of intermediate or high-risk myelofibrosis (MF), including primary myelofibrosis (PMF) or secondary myelofibrosis (post- polycythemia vera/ essential thrombocytopenia (PV/ET)), with anemia.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications